Federal Project Grant Award Summary

Massachusetts General Hospital (MGH) received a $1.35M project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) awarded on July 1, 2026, with a completion date of June 30, 2029. The award funds research to develop explainable artificial intelligence (AI) systems for predicting melanoma progression and survival outcomes. This research aligns with the Defense Health Agency's mission to advance innovative biomedical solutions addressing critical health challenges, with particular emphasis on oncology research relevant to military service members and the broader American public. The research will be conducted at MGH's Research Management Division in Boston, Massachusetts.

The project delivers translational research services that bridge AI algorithm development with clinical applications for melanoma patient stratification and prognostication. As a premier academic medical center with established expertise in precision medicine and oncology research, MGH will leverage institutional capabilities in biomedical research infrastructure to advance the interpretability and clinical utility of AI-driven predictive models. This research contributes to the Military Medical Research and Development program's portfolio of hypothesis-driven investigations designed to transform healthcare through innovative medical solutions, with deliverables expected over the three-year performance period.